KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly

Atherosclerosis

Volumn 220, Issue 2, 2012, Pages 456-462

  Akao, Hironobu ^a,b   Polisecki, Eliana ^a,c   Kajinami, Kouji ^b   Trompet, Stella ^d   Robertson, Michele ^e   Ford, Ian ^e   Jukema, J Wouter ^d   de Craen, Anton J M ^d   Westendorp, Rudi G J ^d   Shepherd, James ^e   Packard, Christopher ^e   Buckley, Brendan M ^f   Schaefer, Ernst J ^a,c  

^a TUFTS UNIVERSITY   (United States)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c Boston Heart Diagnostics   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Heart disease risk reduction; KIF6 Gene; Low density lipoprotein cholesterol lowering response; Statins

Indexed keywords

KINESIN; KINESIN LIKE PROTEIN 6; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEMBRANE PROTEIN; PLACEBO; PRAVASTATIN; UNCLASSIFIED DRUG; VESICLE ASSOCIATED MEMBRANE PROTEIN 8;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; ELDERLY CARE; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; TASTE BUD; TREATMENT RESPONSE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, LDL; EUROPE; FEMALE; HOMOZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; KINESIN; LINKAGE DISEQUILIBRIUM; LIPOPROTEIN(A); MALE; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRAVASTATIN; PROSPECTIVE STUDIES; R-SNARE PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84855953137     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.11.037     Document Type: Article

References (25)

1. Ingelsson E., Schaefer E.J., Contois J.H., et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007, 298:776-785.
2. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
3. Bare L.A., Morrison A.C., Rowland C.M., et al. Five common gene variants identify elevated genetic risk for coronary heart disease. Genet Med 2007, 9:682-689.
4. Shiffman D., Chasman D.I., Zee R.Y., et al. A kinesin family member 6 variant is associated with coronary heart disease in the Women's Health Study. J Am Coll Cardiol 2008, 51:444-448.
5. Shiffman D., O'Meara E.S., Bare L.A., et al. Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2008, 28:173-179.
6. Assimes T.L., Hólm H., Kathiresan S., et al. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol 2010, 56:1552-1563.
7. Iakoubova O.A., Tong C.H., Rowland C.M., et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol 2008, 51:435-443.
8. Shiffman D., Sabatine M.S., Louie J.Z., et al. Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial. Am J Cardiol 2010, 105:1300-1305.
9. Iakoubova O.A., Sabatine M.S., Rowland C.M., et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2008, 51:444-448.
10. Iakoubova O.A., Robertson M., Tong C.H., et al. KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study. Eur J Cardiovasc Prev Rehabil 2010, 17:455-461.
11. Hopewell J.C., Parish S., Clarke R., et al. No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study. J Am Coll Cardiol 2011, 57:2000-2007.
12. Ridker P.M., Macfadyen J.G., Glynn R.J., et al. Kinesin-like protein 6 (KIF6) Polymorphism and the efficacy of rosuvastatin in primary prevention. Circ Cardiovasc Genet 2011, 4:312-317.
13. Shepherd J., Blauw G.J., Murphy M.B., et al. PROspective study of pravastatin in the elderly at risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630.
14. Shepherd J., Blauw G.J., Murphy M.B., et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol 1999, 84:1192-1197.
15. Havekes L.M., de Knijff P., Beisiegel U., et al. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res 1987, 28:455-463.
16. Lahoz C., Osgood D., Wilson P.W., et al. Frequency of phenotype-genotype discrepancies at the apolipoprotein E locus in a large population study. Clin Chem 1996, 42:1817-1823.
17. Ordovas J.M., Lopez-Miranda J., Perez-Jimenez F., et al. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 1995, 113:157-166.
18. Pedro-Botet J., Schaefer E.J., Bakker-Arkema R.G., et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 2001, 158:183-193.
19. Wilson P.W., Schaefer E.J., Larson M.G., et al. Apolipoprotein E alleles and risk of coronary disease: a meta-analysis. Arterioscler Thromb Vasc Biol 1996, 16:1250-1255.
20. Lahoz C., Schaefer E.J., Cupples L.A., et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 2001, 154:529-537.
21. Lewontin R.C. The interaction of selection and linkage. II. Optimum models. Genetics 1964, 50:757-782.
22. Expert Panel Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
23. Polisecki E., Muallem H., Maeda N., et al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis 2008, 200:109-114.
24. Polisecki E., Peter I., Robertson M., et al. Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population. Atherosclerosis 2008, 200:95-101.
25. Polisecki E., Peter I., Simon J.S., et al. Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly. J Lipid Res 2010, 51:1201-1207.